Cargando…

Nonmetastatic pancreatic cancer: Improved survival with chemoradiotherapy > 40 Gy after systemic treatment

PURPOSE: The role of radiotherapy (RT) for nonmetastatic pancreatic cancer is still a matter of debate since randomized control trials have shown inconsistent results. The current retrospective single-institution study includes both resected and unresected patients with nonmetastasized pancreatic ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bachmayer, Sebastian, Fastner, Gerd, Vaszi, Andrea, Iglseder, Wolfgang, Kopp, Peter, Holzinger, Josef, Dinnewitzer, Adam, Rinnerthaler, Gabriel, Gampenrieder, Simon Peter, Emmanuel, Klaus, Greil, Richard, Sedlmayer, Felix, Zehentmayr, Franz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008353/ https://www.ncbi.nlm.nih.gov/pubmed/29497791 http://dx.doi.org/10.1007/s00066-018-1281-7

Ejemplares similares

miR-16-5p Is a Stably-Expressed Housekeeping MicroRNA in Breast Cancer Tissues from Primary Tumors and from Metastatic Sites
por: Rinnerthaler, Gabriel, et al.
Publicado: (2016)

Boost IORT in Breast Cancer: Body of Evidence
por: Sedlmayer, Felix, et al.
Publicado: (2014)

Radiation dose escalation with modified fractionation schedules for locally advanced NSCLC: A systematic review
por: Zehentmayr, Franz, et al.
Publicado: (2020)

The potential predictive value of tumor budding for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer
por: Jäger, Tarkan, et al.
Publicado: (2018)

DART-bid (Dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily)–a novel approach for non-resected NSCLC: final results of a prospective study, correlating radiation dose to tumor volume
por: Wurstbauer, Karl, et al.
Publicado: (2013)

Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy
por: Huemer, Florian, et al.
Publicado: (2020)

Intraoperative radiotherapy (IORT) as boost in breast cancer
por: Sedlmayer, Felix, et al.
Publicado: (2017)

Impact of reirradiation, chemotherapy, and immunotherapy on survival of patients with recurrent lung cancer: A single‐center retrospective analysis
por: Grambozov, Brane, et al.
Publicado: (2021)

Survival in early lung cancer patients treated with high dose radiotherapy is independent of pathological confirmation
por: Zehentmayr, Franz, et al.
Publicado: (2019)

CDK4/6 inhibition in luminal breast cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2016)

HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
por: Rinnerthaler, Gabriel, et al.
Publicado: (2019)

SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis
por: Rinnerthaler, Gabriel, et al.
Publicado: (2018)

ASCO 2018 highlights: metastatic breast cancer
por: Rinnerthaler, Gabriel, et al.
Publicado: (2018)

SABCS 2016: systemic therapy for metastatic breast cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2017)

Cure in metastatic breast cancer
por: Westphal, Theresa, et al.
Publicado: (2018)

Treatment Landscape for Patients with HER2-Positive Metastatic Breast Cancer: A Review on Emerging Treatment Options
por: Gampenrieder, Simon Peter, et al.
Publicado: (2020)

Neoadjuvant Chemotherapy and Targeted Therapy in Breast Cancer: Past, Present, and Future
por: Gampenrieder, Simon P., et al.
Publicado: (2013)

Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone: Analysis of the Austrian head and neck cancer registry of the AGMT
por: Magnes, Teresa, et al.
Publicado: (2021)

High Dose Thoracic Re-Irradiation and Chemo-Immunotherapy for Centrally Recurrent NSCLC
por: Grambozov, Brane, et al.
Publicado: (2022)

Carbon Monoxide Diffusing Capacity (DL(CO)) Correlates with CT Morphology after Chemo-Radio-Immunotherapy for Non-Small Cell Lung Cancer Stage III
por: Stana, Markus, et al.
Publicado: (2022)

Chemo-Radio-Immunotherapy for NSCLC III: ESR/ATS Thresholds for DL(CO) Correlate with Radiation Dosimetry and Pneumonitis Rate
por: Stana, Markus, et al.
Publicado: (2023)

Hsa-miR-3651 could serve as a novel predictor for in-breast recurrence via FRMD3
por: Zellinger, Barbara, et al.
Publicado: (2021)

Hsa-miR-375/RASD1 Signaling May Predict Local Control in Early Breast Cancer
por: Zellinger, Barbara, et al.
Publicado: (2020)

Pulmonary function decreases moderately after accelerated high‐dose irradiation for stage III non‐small cell lung cancer
por: Grambozov, Brane, et al.
Publicado: (2019)

Re-Irradiation for Locally Recurrent Lung Cancer: A Single Center Retrospective Analysis
por: Grambozov, Brane, et al.
Publicado: (2021)

Hsa-miR-375 is a predictor of local control in early stage breast cancer
por: Zehentmayr, Franz, et al.
Publicado: (2016)

Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid)
por: Zehentmayr, Franz, et al.
Publicado: (2015)

Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer
por: Huemer, Florian, et al.
Publicado: (2018)

DART-bid for loco-regionally advanced NSCLC: Summary of acute and late toxicity with long-term follow-up; experiences with pulmonary dose constraints
por: Wurstbauer, Karl, et al.
Publicado: (2017)

Durvalumab after Sequential High Dose Chemoradiotherapy versus Standard of Care (SoC) for Stage III NSCLC: A Bi-Centric Trospective Comparison Focusing on Pulmonary Toxicity
por: Wass, Romana, et al.
Publicado: (2022)

Hematologic Markers as Prognostic Factors in Nonmetastatic Esophageal Cancer Patients under Concurrent Chemoradiotherapy
por: Wu, Yi-Feng, et al.
Publicado: (2019)

Reply to: The challenge of cardiac dose constraint adaptation to hypofractionated breast radiotherapy in clinical practice
por: Piroth, Marc D., et al.
Publicado: (2021)

Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade
por: Huemer, Florian, et al.
Publicado: (2019)

Supervised versus autonomous exercise training in breast cancer patients: A multicenter randomized clinical trial
por: Westphal, Theresa, et al.
Publicado: (2018)

Impact of the Siewert Classification on the Outcome of Patients Treated by Preoperative Chemoradiotherapy for a Nonmetastatic Adenocarcinoma of the Oesophagogastric Junction
por: Moureau-Zabotto, Laurence, et al.
Publicado: (2015)

Antiangiogenic therapy in breast cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2017)

Risk-adapted moderate hypofractionation of prostate cancer: A prospective analysis of acute toxicity, QOL and outcome in 221 patients
por: Schörghofer, Andreas, et al.
Publicado: (2019)

DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2018)

Comparison of high tone therapy and transcutaneous electrical nerve stimulation therapy in chemotherapy-induced polyneuropathy
por: Schaffler-Schaden, Dagmar, et al.
Publicado: (2020)

Comparison of the effects of radiotherapy doses of 50.4 Gy and 60 Gy on outcomes of chemoradiotherapy for thoracic esophageal cancer: subgroup analysis based on the Comprehensive Registry of Esophageal Cancer in Japan from 2009 to 2011 by the Japan Esophageal Society
por: Nemoto, Kenji, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fugbt99fbjftqsddjqgjp4nhg0